This slide show highlights 2016 FDA approvals of cancer treatments, which to date include therapies for RCC, neuroendocrine tumors, Hodgkin lymphoma, CLL, sarcoma, bladder cancer, lung cancer, and breast cancer.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Source Type: news

Related Links:

Authors: Zhu D, Kong CSL, Gingold JA, Zhao R, Lee DF
Abstract
In 2006, Noble Prize laureate Shinya Yamanaka discovered that a set of transcription factors can reprogram terminally differentiated somatic cells to a pluripotent stem cell state. Since then, induced pluripotent stem cells (iPSCs) have come into the public spotlight. Amidst a growing field of promising clinical uses of iPSCs in recent years, cancer disease modeling has emerged as a particularly promising and rapidly translatable application of iPSCs. Technological advances in genome editing over the past few years have facilitated increasingly rapid pro…

ConclusionAll these findings propose that tumor cells are subjected to metabolic reprogramming after LMW-PTP silencing, enhancing glycolytic flux, probably to compensate the inhibition of mitochondrial metabolism.General significance.Our results highlight the involvement of LMW-PTP in regulating glucose metabolism in A375 melanoma cells.

In conclusion, this study provides an insight about the role of exogenous H2S in TNBC cell lines highlighting a novel crosstalk between H2S and NO orchestrated by sONE/NOS3 axis.

Source: Nitric OxideCategory: Chemistry Source Type: research

Authors: Noguerido A, Mulet-Margalef N, Matos I, Ros J, Argilés G, Élez E, Tabernero J
Abstract
INTRODUCTION: Ramucirumab, a human monoclonal antibody against vascular endothelial growth factor receptor 2 (VEGFR-2), is an antiangiogenic therapy that has been approved in combination with FOLFIRI in second-line treatment of metastatic colorectal cancer (mCRC), after progression on or after therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. A thorough review of the safety of ramucirumab in this setting and in the context of other antiangiogenic agents is merited. Areas covered: We provide an o…

Publication date: Available online 4 August 2018Source: Journal of Photochemistry and Photobiology B: BiologyAuthor(s): Jayanta Kumar Patra, Gitishree Das, Anuj Kumar, AbuZar Ansari, Hojun Kim, Han-Seung ShinAbstractSilver nanoparticles (AgNPs) have been synthesized by various ways but the green technology methods using food waste materials has been accepted now a days for their cost effectiveness, environmental friendly and effective biomedical application. In the present study an attempt has been made to synthesize AgNPs by using the outer accrescent fruiting calyx of Physalis peruviana fruits, a food waste material unde…

Publication date: Available online 3 August 2018Source: European UrologyAuthor(s): Arnout R. Alberts, Monique J. Roobol, Jan F.M. Verbeek, Ivo G. Schoots, Peter K. Chiu, Daniël F. Osses, Jasper D. Tijsterman, Harrie P. Beerlage, Christophe K. Mannaerts, Lars Schimmöller, Peter Albers, Christian ArsovAbstractBackgroundThe Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculators (ERSPC-RCs) help to avoid unnecessary transrectal ultrasound-guided systematic biopsies (TRUS-Bx). Multivariable risk stratification could also avoid unnecessary biopsies following multiparametric magnetic reson…

Source: European UrologyCategory: Urology & Nephrology Source Type: research

Publication date: Available online 3 August 2018Source: Preventive MedicineAuthor(s): Jennifer L. Moss, Qian Xiao, Charles E. MatthewsAbstractMultiple health behaviors could have greater impact on chronic diseases than single behaviors, but correlates of behavioral clusters are relatively understudied. Using data from NIH-AARP Diet and Health Study (initiated in 1995) for 324,522 participants from the U.S. (age 50–71), we conducted exploratory factor analysis to identify clusters of adherence to eight cancer prevention behaviors. Poisson regressions examined associations between cluster scores and neighborhood socioe…

Source: Preventive MedicineCategory: International Medicine & Public Health Source Type: research

Publication date: Available online 3 August 2018Source: Journal of the American College of RadiologyAuthor(s): Taylor R. Cushman, Joseph Mashni, Terence Roberts, Rachit Kumar

ConclusionManagement is rarely changed by one-month post-SIRT imaging in patients with HCC and thus is likely unwarranted. Conversely, in non-HCC patients, one month post-SIRT imaging led to a significant percentage of clinical management changes suggesting that one month imaging in this setting is likely warranted.

Chemotherapy is one of the most powerful tools we have to treat cancer, and research continues to find new chemotherapy drugs as well as new uses for existing ones. At the same time, newer types of drugs are continually being developed that work in different ways to attack cancer cells.They include targeted therapy, which aims to more precisely identify cancer cells while doing less damage to normal cells, and immunotherapy, which uses the body’s own immune system to help find and destroy cancer.Before any new drug can be sold in the United States, it has to go through an approval process by the Food and Drug Adminis…





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image